The Ability of Preoperative Serum CA-125 to Predict Optimal Primary Tumor Cytoreduction in Stage III Epithelial Ovarian Carcinoma

This publication has 14 references indexed in Scilit:

• Neoadjuvant Chemotherapy for Advanced Ovarian Cancer: Long-Term Survival
  Gynecologic Oncology, 1999
• Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Carcinoma: A Retrospective Analysis of 285 Patients
  Gynecologic Oncology, 1998
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996
• The Effect of Debulking Surgery after Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer
  New England Journal of Medicine, 1995
• Epithelial Ovarian Carcinoma: Principles of Primary Surgery
  Gynecologic Oncology, 1994
• The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma
  American Journal of Obstetrics and Gynecology, 1994
• The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: A gynecologic oncology group study
  Gynecologic Oncology, 1992
• Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer
  American Journal of Obstetrics and Gynecology, 1989
• Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: Relevance for early detection of ovarian cancer
  International Journal of Cancer, 1988
• A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
  New England Journal of Medicine, 1983